Dr. David Murray

print version
'Dr. David Murray' image

David received a BSc in Analytical Science from the School of Chemical Sciences at Dublin City University (DCU) in 2000. He then completed his doctoral studies in 2004 at the School of Biotechnology at DCU under the supervision of Dr Susan McDonnell. David's PhD focused on the molecular mechanisms of human colorectal cancer invasion and on identifying novel biomarkers of functional importance. During his doctoral studies David spent five months at the Center for Biomedical Genomics at George Mason University in Virginia using gene array technology to identify key genes and gene clusters that underpin metastasis. 

During his postdoctoral studies, under the supervision of Prof Padraic MacMathuna and Dr Peter Doran at the University College Dublin (UCD) School of Medicine and Medical Research, David focused on understanding gastrointestinal tumour progression through the application of computational biology, transcriptome profiling and gene activity modification. This work resulted in the identification of novel gastrointestinal cancer associated genes including NET1 a RhoGEF that mediates gastric tumour cell invasion.

In 2008 David took up the management role of Senior Research Scientist at the UCD Clinical Research Centre, based at two of Dublin's leading teaching hospitals; The Mater Misericordiae and St Vincents University Hospitals. As well as managing two research laboratories, this role allowed David to continue his research on tumour cell invasion. David's other duties included hiring and supervising postgraduate and postdoctoral researchers, laboratory technical staff and organizing the biobanking of specimens associated with ongoing studies. In conjunction with the Wellcome Dublin Centre for Clinical Research David coordinated the harmonization of study-specific biocollection and central processing of specimens from five Dublin hospital sites. David was also part of the GeneLibrary Ireland committee that successfully acquired Health Research Board (HRB) funding to roll-out the planning phase of this study. In conjunction with Molecular Medicine Ireland David co-authored the first national biobanking guidelines.

In 2010 David was awarded a Marie Curie - HRB mobility fellowship allowing him to spend over two years as a Visiting Scientist in the laboratory of Prof Marc Symons at the Feinstein Institute for Medical Research in New York. While there David identified RhoGEFs of functional importance in human glioblastoma (GBM) invasion and proliferation. In 2013 David returned to RCSI as a Senior Research Fellow and his current efforts involve using a novel anti-invasion nanoparticle mediated approach to deliver GEF specific siRNA in clinically relevant in vivo models of GBM. 

In October 2013 David began an 8 month ANGIOTOX secondment position as a More Experienced Researcher at Oncomark Ltd, a private Irish company centred on the development and application of biomarker panels supporting oncology clinical decisions and drug development. David is investigating mechanisms and biomarkers of cardio-toxicities associated with anti-angiogenic therapies.